Search - tctmd.com

Displaying 1 - 20 of 174

Sort: Relevancy | Date

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

Making Sense of Masters Athletes’ Cardiac Imaging: Expert Review

News Daily News

Making Sense of Masters Athletes’ Cardiac Imaging: Expert Review

Michael O'Riordan

December 11, 2025

European Experts Provide Advice on Managing CV Effects of COVID-19

News Daily News

European Experts Provide Advice on Managing CV Effects of COVID-19

September 19, 2025

Evolocumab Gains Expanded Indication for Primary Prevention

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

$Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis$

News Daily News

Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis

August 13, 2025

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

Ataciguat Shows Potential for Curbing Progression of Aortic Stenosis

News Daily News

Ataciguat Shows Potential for Curbing Progression of Aortic Stenosis

Yael L. Maxwell

February 27, 2025

Invasive Testing Safely Diagnoses Microvascular Dysfunction in ANOCA

News Daily News

Invasive Testing Safely Diagnoses Microvascular Dysfunction in ANOCA

Michael O'Riordan

February 24, 2025

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

News Daily News

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

Michael O'Riordan

January 03, 2025

Low Adherence to Secondary Prevention Recommendations Worldwide: INTERASPIRE

News Daily News

Low Adherence to Secondary Prevention Recommendations Worldwide: INTERASPIRE

Yael L. Maxwell

September 23, 2024

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

News Daily News

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Michael O'Riordan

July 01, 2024

Mechanism’s Mojo ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

Erectile Dysfunction Drugs Don’t Mix Well With Nitrates After MI, PCI

News Daily News

Erectile Dysfunction Drugs Don’t Mix Well With Nitrates After MI, PCI

January 16, 2024

Millions of Lives Lost to CVD Each Year: ‘Almanac’ Updates Global Burden

News Daily News

Millions of Lives Lost to CVD Each Year: ‘Almanac’ Updates Global Burden

December 12, 2023

Prescribing a Generic for CVD? Plan, Drug Type, and Condition Impact Availability

News Daily News

Prescribing a Generic for CVD? Plan, Drug Type, and Condition Impact Availability

September 13, 2023

‘Functional’ SYNTAX Score May Hone PCI, CABG Choices in Multivessel Disease

News Daily News

‘Functional’ SYNTAX Score May Hone PCI, CABG Choices in Multivessel Disease

Michael O'Riordan

September 13, 2023

Deferred Testing in Low-Risk Patients Safe, May Curb Symptoms: PRECISE

News Daily News

Deferred Testing in Low-Risk Patients Safe, May Curb Symptoms: PRECISE

Yael L. Maxwell

August 23, 2023

Pitavastatin Cuts MACE in HIV-Infected Patients REPRIEVE

News Daily News

Pitavastatin Cuts MACE in HIV-Infected Patients: REPRIEVE

Michael O'Riordan

July 25, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.